Home / Stocks / EW

Edwards Lifesciences (EW, Health Care Equipment) Stock Valuation & Fair Value Significantly overvalued

Edwards Lifesciences (EW, Health Care Equipment) trades at a blended P/E of 31.6, about 1% below its historical normal valuation, with a forward growth estimate of 12.8% and a PEG of 2.47. Analysts' one-year estimates have been hit 55% of the time.

DATA AS OF 2026-08-21
Blended P/E
31.6
Normal P/E
32.0
PEG
2.47
Fwd growth
12.8%
Div yield
0.0%
RSI (14)
55.7
Neutral

The Street vs SeerForecast

Wall Street's mean price target for EW is $100.96 across 26 analysts, 12.4% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-06-03.

Price and rating by weekClose moved +6.5 percent from 2026-06-03 to 2026-08-17, with 0 rating changes over 21 recorded weeks.2026-06-03: Significantly overvalued, close 86.00 (recalculated)2026-06-10: Significantly overvalued, close 85.98 (recalculated)2026-06-14: Significantly overvalued, close 85.11 (recalculated)2026-06-16: Significantly overvalued, close 88.58 (recalculated)2026-06-21: Significantly overvalued, close 87.36 (recalculated)2026-07-02: Significantly overvalued, close 94.37 (recalculated)2026-07-06: Significantly overvalued, close 95.18 (recalculated)2026-07-09: Significantly overvalued, close 91.33 (recalculated)2026-07-12: Significantly overvalued, close 92.21 (recalculated)2026-07-13: Significantly overvalued, close 91.79 (recalculated)2026-07-14: Significantly overvalued, close 90.09 (recalculated)2026-07-20: Significantly overvalued, close 85.00 (recalculated)2026-07-22: Significantly overvalued, close 84.37 (recalculated)2026-07-25: Significantly overvalued, close 82.63 (recalculated)2026-07-27: Significantly overvalued, close 83.04 (recalculated)2026-07-31: Significantly overvalued, close 86.07 (recalculated)2026-08-03: Significantly overvalued, close 86.072026-08-07: Significantly overvalued, close 89.72 (recalculated)2026-08-10: Significantly overvalued, close 89.722026-08-14: Significantly overvalued, close 91.60 (recalculated)2026-08-17: Significantly overvalued, close 91.6086922026-06-032026-08-17
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

2026-06-03P/E 31.4-2%Significantly overvalued
2026-06-10P/E 31.3-2%Significantly overvalued
2026-06-14P/E 31.3-2%Significantly overvalued
2026-06-16P/E 31.3-2%Significantly overvalued
2026-06-21P/E 31.3-2%Significantly overvalued
2026-07-02P/E 33.1+3%Significantly overvalued
2026-07-06P/E 33.9+6%Significantly overvalued
2026-07-09P/E 33.9+6%Significantly overvalued
2026-07-12P/E 33.0+3%Significantly overvalued
2026-07-13P/E 33.0+3%Significantly overvalued
2026-07-14P/E 33.0+3%Significantly overvalued
2026-07-20P/E 30.6-4%Significantly overvalued
2026-07-22P/E 30.6-4%Significantly overvalued
2026-07-25P/E 29.4-8%Significantly overvalued
2026-07-27P/E 29.4-8%Significantly overvalued
2026-07-31P/E 30.9-4%Significantly overvalued
2026-08-03P/E 30.6-5%Significantly overvalued
2026-08-07P/E 31.6-1%Significantly overvalued
2026-08-10P/E 31.8-1%Significantly overvalued
2026-08-14P/E 32.7+2%Significantly overvalued
2026-08-17P/E 32.3+1%Significantly overvalued
2026-08-21P/E 31.6-1%Significantly overvalued ← now

Frequently asked questions

Is Edwards Lifesciences stock overvalued?

At a blended P/E of 31.6 versus its historical normal P/E of 32.0, Edwards Lifesciences trades about 1% below its typical valuation, with a PEG of 2.47 on 12.8% forward growth. tickerseer currently rates it significantly overvalued.

What is Edwards Lifesciences's fair value and PEG?

Edwards Lifesciences trades at a blended P/E of 31.6 against a historical normal P/E of 32.0, a PEG of 2.47, and a forward growth estimate of 12.8%.

Has tickerseer's rating of Edwards Lifesciences changed?

tickerseer's rating has been significantly overvalued since 2026-06-03.

What is the analyst price target for Edwards Lifesciences?

The mean Wall Street price target for Edwards Lifesciences is $100.96 across 26 analysts, 12.4% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Health Care Equipment. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track EW free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. Educational content, not investment advice.